{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T09:59:14Z","timestamp":1780653554209,"version":"3.54.1"},"reference-count":19,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2000,1,1]],"date-time":"2000-01-01T00:00:00Z","timestamp":946684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2000,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            The in vitro antifungal activity and spectrum of FK463 were compared with those of amphotericin B, fluconazole, and itraconazole by using a broth microdilution method specified by National Committee for Clinical Laboratory Standards document M27-A (National Committee for Clinical Laboratory Standards, Wayne, Pa., 1997). FK463 exhibited broad-spectrum activity against clinically important pathogens including\n            <jats:italic>Candida<\/jats:italic>\n            species (MIC range, \u22660.0039 to 2 \u03bcg\/ml) and\n            <jats:italic>Aspergillus<\/jats:italic>\n            species (MIC range, \u22660.0039 to 0.0313 \u03bcg\/ml), and its MICs for such fungi were lower than those of the other antifungal agents tested. FK463 was also potently active against azole-resistant\n            <jats:italic>Candida albicans<\/jats:italic>\n            as well as azole-susceptible strains, and there was no cross-resistance with azoles. FK463 showed fungicidal activity against\n            <jats:italic>C. albicans<\/jats:italic>\n            , i.e., a 99% reduction in viability after a 24-h exposure at concentrations above 0.0156 \u03bcg\/ml. The minimum fungicidal concentration (MFC) assays indicated that FK463 was fungicidal against most isolates of\n            <jats:italic>Candida<\/jats:italic>\n            species. In contrast, the MFCs of FK463 for\n            <jats:italic>A. fumigatus<\/jats:italic>\n            isolates were much higher than the MICs, indicating that its action is fungistatic against this species. FK463 had no activity against\n            <jats:italic>Cryptococcus neoformans<\/jats:italic>\n            ,\n            <jats:italic>Trichosporon<\/jats:italic>\n            species, or\n            <jats:italic>Fusarium solani<\/jats:italic>\n            . Neither the test medium (kind and pH) nor the inoculum size greatly affected the MICs of FK463, while the addition of 4% human serum albumin increased the MICs for\n            <jats:italic>Candida<\/jats:italic>\n            species and\n            <jats:italic>A. fumigatus<\/jats:italic>\n            more than 32 times. Results from preclinical in vitro evaluations performed thus far indicate that FK463 should be a potent parenteral antifungal agent.\n          <\/jats:p>","DOI":"10.1128\/aac.44.1.57-62.2000","type":"journal-article","created":{"date-parts":[[2009,4,22]],"date-time":"2009-04-22T05:03:57Z","timestamp":1240376637000},"page":"57-62","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":253,"title":["In Vitro Activities of a New Lipopeptide Antifungal Agent, FK463, against a Variety of Clinically Important Fungi"],"prefix":"10.1128","volume":"44","author":[{"given":"Shuichi","family":"Tawara","sequence":"first","affiliation":[{"name":"<!--label omitted: 1-->Medicinal Biology Research Laboratories1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Ikeda","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Medicinal Biology Research Laboratories1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuyuki","family":"Maki","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Medicinal Biology Research Laboratories1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Morishita","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Medicinal Biology Research Laboratories1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumi","family":"Otomo","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Medicinal Biology Research Laboratories1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Teratani","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Medicinal Biology Research Laboratories1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Goto","sequence":"additional","affiliation":[{"name":"<!--label omitted: 1-->Medicinal Biology Research Laboratories1 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Tomishima","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Medicinal Chemistry Research Laboratories,2 Fujisawa Pharmaceutical Co., Ltd., 1-6, 2-Chome Kashima, Yodogawa-ku, Osaka 532-8514,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Ohki","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Medicinal Chemistry Research Laboratories,2 Fujisawa Pharmaceutical Co., Ltd., 1-6, 2-Chome Kashima, Yodogawa-ku, Osaka 532-8514,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yamada","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Medicinal Chemistry Research Laboratories,2 Fujisawa Pharmaceutical Co., Ltd., 1-6, 2-Chome Kashima, Yodogawa-ku, Osaka 532-8514,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kawabata","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Medicinal Chemistry Research Laboratories,2 Fujisawa Pharmaceutical Co., Ltd., 1-6, 2-Chome Kashima, Yodogawa-ku, Osaka 532-8514,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Takasugi","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Medicinal Chemistry Research Laboratories,2 Fujisawa Pharmaceutical Co., Ltd., 1-6, 2-Chome Kashima, Yodogawa-ku, Osaka 532-8514,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Sakane","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Medicinal Chemistry Research Laboratories,2 Fujisawa Pharmaceutical Co., Ltd., 1-6, 2-Chome Kashima, Yodogawa-ku, Osaka 532-8514,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Tanaka","sequence":"additional","affiliation":[{"name":"<!--label omitted: 2-->Medicinal Chemistry Research Laboratories,2 Fujisawa Pharmaceutical Co., Ltd., 1-6, 2-Chome Kashima, Yodogawa-ku, Osaka 532-8514,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumio","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"<!--label omitted: 3-->Kanagawa Prefectural Nursing and Hygienic School Hospital, 1-6, Shiomidai, Isogo-ku, Yokohama 235-0022,3 and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shogo","family":"Kuwahara","sequence":"additional","affiliation":[{"name":"<!--label omitted: 4-->Toho University School of Medicine, 21-16, 5-Chome Ohmori Nishi, Ohta-ku, Tokyo 143-8540,4 Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2333"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.11.2326"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.5.1070"},{"key":"e_1_3_2_5_2","first-page":"133","article-title":"Correlation of cilofungin in vivo efficacy with its activity against Aspergillus fumigatus (1,3)-\u03b2-d-glucan synthase.","volume":"108","author":"Beaulieu D.","year":"1993","unstructured":"Beaulieu D. Tang J. Zeckner D. J. Parr T. R. Jr. Correlation of cilofungin in vivo efficacy with its activity against Aspergillus fumigatus (1,3)-\u03b2-d-glucan synthase. FEMS Microbiol. Lett. 108 1993 133 138","journal-title":"FEMS Microbiol. Lett."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.mi.48.100194.002351"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.37.9.1962"},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/BF01964276","article-title":"In vitro activity of the new semisynthetic polypeptide cilofungin (LY121019) against Aspergillus and Candida species.","volume":"9","author":"Huang A.","year":"1990","unstructured":"Huang A. Edwards F. Bernard E. M. Armstrong D. Schmitt H. J. In vitro activity of the new semisynthetic polypeptide cilofungin (LY121019) against Aspergillus and Candida species. Eur. J. Clin. Microbiol. Infect. Dis. 9 1990 697 699","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1128\/JCM.36.10.2950-2956.1998","article-title":"Comparison of the in vitro activities of the new triazole SCH56592 and the echinocandin MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.","volume":"36","author":"Ingroff A. E.","year":"1998","unstructured":"Ingroff A. E. Comparison of the in vitro activities of the new triazole SCH56592 and the echinocandin MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36 1998 2950 2956","journal-title":"J. Clin. Microbiol."},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.9.1957"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.38.12.2750"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.8.1784"},{"key":"e_1_3_2_13_2","unstructured":"National Committee for Clinical Laboratory Standards\n          Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. NCCLS document M27-A.\n          1997\n          National Committee for Clinical Laboratory Standards\n          Wayne Pa"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.10.2726"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.11.2898"},{"key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1128\/AAC.41.8.1835","article-title":"In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds.","volume":"41","author":"Poeta M. D.","year":"1997","unstructured":"Poeta M. D. Schell W. A. Perfect J. R. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob. Agents Chemother. 41 1997 1835 1836","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/17.3.269"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.12.2689"},{"key":"e_1_3_2_19_2","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1128\/AAC.42.4.873","article-title":"Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.","volume":"42","author":"Verweiji P. E.","year":"1998","unstructured":"Verweiji P. E. Oakley K. L. Morrissey J. Morrissey G. Denning D. W. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob. Agents Chemother. 42 1998 873 878","journal-title":"Antimicrob. Agents Chemother."},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.4.863"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.1.57-62.2000","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.44.1.57-62.2000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:30:52Z","timestamp":1645461052000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.44.1.57-62.2000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2000,1]]}},"alternative-id":["10.1128\/AAC.44.1.57-62.2000"],"URL":"https:\/\/doi.org\/10.1128\/aac.44.1.57-62.2000","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,1]]},"assertion":[{"value":"1999-05-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"1999-10-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2000-01-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}